Middle East & Africa Cell And Gene Therapy Cdmo Market Size & Outlook
The cell and gene therapy cdmo market in Middle East & Africa is expected to reach a projected revenue of US$ 258.9 million by 2033. A compound annual growth rate of 14.2% is expected of Middle East & Africa cell and gene therapy cdmo market from 2025 to 2033.
The MEA cell and gene therapy cdmo market generated a revenue of USD 78.3 million in 2024.
The market is expected to grow at a CAGR of 14.2% from 2025 to 2033.
In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
Country-wise, UAE is expected to register the highest CAGR from 2025 to 2033.
MEA data book summary
Market revenue in 2024
USD 78.3 million
Market revenue in 2033
USD 258.9 million
Growth rate
14.2% (CAGR from 2025 to 2033)
Largest segment
Pre-clinical
Fastest growing segment
Pre-clinical
Historical data covered
2021 - 2023
Base year for estimation
2024
Forecast period covered
2025 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Pre-clinical, Clinical
Key market players worldwide
Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc
Other key industry trends
In terms of revenue, MEA region accounted for 1.8% of the global cell and gene therapy cdmo market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 4,989.5 million by 2033.
Middle Eastern countries such as South Africa, Saudi Arabia, the United Arab Emirates (UAE), and Kuwait are prospering economies. The cell & gene therapy CDMO market in the MEA is likely to grow steadily in the forthcoming period.
The increasing burden of diseases and the demand for drugs are some major factors contributing to market growth. In addition, the growing number of clinical trials is anticipated to boost the market over the forecast period.
According to the WHO International Clinical Trials Registry Platform (ICTRP), there were 861 clinical trials registered in Africa in 2022. Moreover, less competition between pharmaceutical companies in underdeveloped countries of the region is attracting various pharmaceutical startups, resulting in regional market growth.
Middle East & Africa Cell And Gene Therapy CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy CDMO Market Outlook will help companies and investors design strategic landscapes.
Pre-Clinical was the largest segment with a revenue share of 73.05% in 2024.
Horizon Databook has segmented the Middle East & Africa cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
Middle Eastern countries such as South Africa, Saudi Arabia, the United Arab Emirates (UAE), and Kuwait are prospering economies. The cell & gene therapy CDMO market in the MEA is likely to grow steadily in the forthcoming period.
The increasing burden of diseases and the demand for drugs are some major factors contributing to market growth. In addition, the growing number of clinical trials is anticipated to boost the market over the forecast period.
According to the WHO International Clinical Trials Registry Platform (ICTRP), there were 861 clinical trials registered in Africa in 2022. Moreover, less competition between pharmaceutical companies in underdeveloped countries of the region is attracting various pharmaceutical startups, resulting in regional market growth.
Middle East & Africa Cell And Gene Therapy Cdmo Market Phase Outlook (Revenue, USD Million , 2021-2033)
Pre-clinical
Clinical
Middle East & Africa Cell And Gene Therapy Cdmo Market Indication Outlook (Revenue, USD Million , 2021-2033)
Rare Diseases
Others
Oncology
Infectious Diseases
Neurological disorders
Middle East & Africa Cell And Gene Therapy Cdmo Market Product Type Outlook (Revenue, USD Million , 2021-2033)
Gene Therapy
Gene-Modified Cell Therapy
Cell Therapy
Reasons to subscribe to Cell And Gene Therapy CDMO Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy CDMO Market Outlook databook
Our clientele includes a mix of Cell And Gene Therapy CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Cell And Gene Therapy CDMO Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Cell And Gene Therapy CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Middle East Africa Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)